Much attention has gone to Regeneron and the monoclonal antibody cocktail known as REGN-CoV2, especially given the investigational drug was recently given to POTUS at Walter Reed Medical Center. Now, its maker Regeneron has the attention of another party called Allele Biotechnology and Pharmaceuticals Inc. (Allele), a privately held firm that has sued in New York for patent infringement. The company claims that the use of its mNeonGreen protein in the development of REGN-COV2 infringed on a patent. Apparently, the patent holder also has moved on the Pfizer/BioNTech partnership in California for another federal patent infringement claim.
When did Allele have its Patent Issued?
March 2019. Allele’s approach to fluorescent protein is considered a “gold standard” for the testing of efficacy of antibody and vaccine targets.
What’s Allele’s Argument?
They have patented a fluorescent protein that is used for injecting into cells to help researchers monitor activities such as how a virus reacts to an antibody. In the case of Pfizer and Biotech, the plaintiff declared in their complaint, “Only through use of mNeonGreen” could the pair progress their vaccine candidate so r...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).